CX717

Cortex's AMPAKINE Molecule CX717 Has Positive Effects in Opiate-Induced Respiratory Depression in a...that a single oral dose of 2100mg of AMPAKINE® CX717 achieved statistical significance over placebo on the...each received either 900mg, 1500mg, or 2100mg of CX717 or matching placebo that was orally administered two ... at 55mgHg CO2 (VE55), was reversed by 2100 mg CX717 in comparison to placebo (p

Cortex to Provide Top Line Data for CX717 Clinical Trial for the Prevention of Opiate-Induced Respiratory Depression in Humans...of two studies in normal volunteers to evaluate the use of AMPAKINE® CX717 to prevent opiate-induced respiratory depression. The study, CX717... unit in Berlin, Germany. A second respiratory depression study, CX717-RD-01, began enrollment several weeks after the Berlin...

FWIW: This the R&R note just sent out on Cortex (well, it finally trickled down to their bottom of the barrel email list, including NI). Clearly they can barely contain their enthusiasm.

... you think that because Cortex is just getting CX717 into an intravenous formulation and hasn't ... the clinic with an intravenous formulation of CX717" in a repost of my post #19998: I e-mailed Mark ... appropriate trial design protocol for a Phase IIb study of CX717 in the treatment of RD? How might CX717...the clinic with an intravenous formulation of CX717, since we have only ever tested...

...the company’s two Phase IIa human clinical trials of AMPAKINE® CX717 as a potential acute treatment for respiratory depression. As recently ... the first clinical study demonstrated that a single oral dose of 2100mg of CX717 has positive effects on respiratory depression induced by alfentanil, a ... volume (VE) at 55mgHg CO2 (VE55), was reversed by 2100mg of CX717 in comparison to placebo (p

...s very clear from Cortex's behavior that he is referring to CX1942 in addition to CX717. Otherwise, there'd be no reason to develop CX717 in IV form. A partner can decide how much to push CX717 out as the first-generation drug, to be followed by CX1942...is not far-fetched, it recognizes the reality that the patent life makes CX717 alone less attractive to a partner. NeuroInvestment

... 9:30 AM (EDT). He will discuss the initial top line results from the first of two studies in normal volunteers to evaluate the use of AMPAKINE® CX717 to prevent opiate-induced respiratory depression. The study, CX717- RD-02, was performed at a clinical research unit in Berlin, Germany.

I don't think R&R was in error. The EU CX717 in ADHD possibility does put pressure on SP, which is fine, but it is a genuine alternative: Partner CX717 (perhaps as a bridge to CX1739) with a EU partner. ... has been. A partner could do a pilot trial with CX717, and then decide (similar to RD) how far to take CX717, whether to license CX1739 (if they didnt already) or to take that ...

I understand the point he was making, and the point I am making is that the statement is still completely false. Before we move on, let's recap the facts: Again, Davey's statement was extremely inaccurate and misleading, since all that mattered in regards to SP was the ADHD decision, and the FDA only responded to AD. Don't know why there is such defense of this, it's all...

Cortex to Provide Top Line Data for CX717 Clinical Trial for the Prevention of Opiate-Induced Respiratory Depression in Humans... of two studies in normal volunteers to evaluate the use of AMPAKINE® CX717 to prevent opiate-induced respiratory depression. The study, CX717- ... unit in Berlin, Germany. A second respiratory depression study, CX717-RD-01, began enrollment several weeks after the ...